Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek licensees for a technology involving the preparation and use of personalized tumor vaccines for cancer immunotherapy employing a therapeutic strategy called MBTA. MBTA consists of vaccinations with irradiated tumor cells pulsed with phagocytic agonists (Mannan-BAM, a polysaccharide derivative of mannan), TLR (Toll-like receptor) ligands, and agonistic Anti-CD40-monoclonal antibody.
Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for single domain antibodies targeting program death ligand 1 (PD-L1) for treatment of PD-L1-expressing cancers.
Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and activates M2-like tumor associated macrophages resulting in innate and adaptive anti-tumor responses. NCI seeks research co-development or licensees for CD206 small molecule modulators as a therapeutic for CD206-expressing cancers (such as pancreatic, sarcoma, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, melanoma).
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for further development of novel iodonium analogs. These iodonium analogs inhibit NADPH oxidases (NOX) and other flavin dehydrogenases to slow tumor growth.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the sulfatide analog, C24:2, that is capable of activating tumor killing type II NKT cells and reducing cancer metastasis to the lung.
Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for oxynitidine derivatives as new topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors for treating cancer. These TOP1 and TDP1 inhibitors administered in combination display increased anti-tumor potency.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.
The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.
Investigators at the National Cancer Institute (NCI) seek co-development partners and/or licensees for a new therapeutic approach that selectively targets cancer cells and prevents tumor regrowth. The novel method combines antibody-IR700 molecules and Near-Infrared Photo Immunotherapy (NIR-PIT), which has shown great potential in targeting tumors via a host immunogenic response, with already known and available anti-cancer immunomodulators to further enhance the antitumor response. The investigators have shown in mouse models that, when used in combination, NIR-PIT-treatment and standard antitumor agents conferred a potent vaccine-like effect, not only curing mice of local and distant cancers but successfully immunizing them against tumor regrowth.
The National Cancer Institute (NCI) seeks licensees for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.
Researchers at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 (also called B7-H3) single domain antibodies (also known as nanobodies). These antibodies have a high affinity for CD276-positive tumor cells and have great potential for diagnostic and therapeutic technologies against solid tumors. The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.
The National Cancer Institute (NCI) seeks research co-development partners or licensees for antisense oligonucleotides that reduce cancer cell migration and invasion. These are expected to be therapeutic against metastatic cancer.
Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.